May 8 (Reuters) - Teva Pharmaceuticals and partner Medincell said on Wednesday their experimental schizophrenia drug had met its main goal in a late-stage study. (Reporting by Puyaan Singh; Editing by Devika Syamnath)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.64 EUR | -1.51% | +0.90% | +117.22% |
May. 15 | Medincell: share price falls after disappointing clinical study | CF |
May. 15 | Transcript : MedinCell S.A. - Special Call |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+117.22% | 502M | |
+42.69% | 750B | |
+34.11% | 606B | |
-6.87% | 356B | |
+18.74% | 326B | |
+6.76% | 286B | |
+18.08% | 246B | |
-3.44% | 213B | |
+11.35% | 213B | |
+2.64% | 167B |
- Stock Market
- Equities
- MEDCL Stock
- News MedinCell S.A.
- Teva and Medincell's schizophrenia drug meets main goal of late-stage study